AICAR, scientifically known as 5-Aminomidaloze-4-carboxamide ribonucleotide, is a peptide that has been utilized in scientific study on animal research subjects in relation to measuring glucose uptake, insulin resistance, and energy regulation. It has also been studied via animal test subject in relation to cardiac ischemic injuries.
AICAR and Glucose Uptake
According to scientific research based on animal test subjects, AICAR has been measured to be capable of increasing the uptake of glucose; one of the three dietary monosaccharides (along with fructose and galactose) that are absorbed directly into the bloodstream during digestion, where it is used by cells as a secondary energy source and a metabolic intermediate. These studies have also shown that AICAR has been measured to increase the synthesis of glycogen; the multibranched polysaccharide that serves as a type of energy storage in animal test subjects. This increased uptake and synthesis has been determined to lead to an elevated rate of protein secretions that relate to the building and repair of skeletal muscle tissue. This in turn has shown that animal test subjects that are introduced to the peptide have a more efficient means of muscular build up as well as muscular repair.
AICAR and Insulin Resistance
Scientific research on animal test subjects has determined that the peptide has positive theoretical benefits in relation to combating insulin resistance. This physiological condition is marked by a cell’s inability to respond to the normal reactions brought about by insulin secretions. Studies conducted on laboratory rats have determined that the peptide has the ability to enhance a proper cellular response to insulin secretions. This action of lowering insulin resistance within an animal test subject directly correlates to AICAR’s ability stimulate glycogen synthesis and improve glucose uptake, which are two factors that are important for the growth and repair of muscular and skeletal tissue.
AICAR and Energy Regulation
Scientific study on animal test subjects has demonstrated that AICAR has an ability to improve glucose update and stimulate the synthesis of glycogen. This, in turn, means that the peptide has the facility to enable a test subject’s body to regulate or escalate the amount of energy that can be expressed during an amount of activity. This process has led to the theory that the subjects’ bodies in relation to their energy-driven processes can also be elevated. These matters of elevation include:
- An increase in endurance – AICAR’s ability to increase expression of protein content and allow for a more efficient energy conversion process allows the muscles of animal test subjects to perform at a consistent rate over a longer course of time, without showing signs of fatigue at typical rates.
- An increase in the burning of fat – Scientific study based on laboratory rats have determined that AICAR’s facility to prolong protein expression led to a more efficient breakdown of adipose tissue (that is, body fat). These studies state that lengthy exposure to AICAR’s activation tendencies can remodel adipocyte metabolism by upregulating pathways that favor the dissipation of energy instead of the storage of body fat.
AICAR and Cardiac Ischemic Injury
Additionally, scientific study on animal test subjects has determined that AICAR’s ability to promote glucose uptake can help in the protection from and the treatment of cardiac ischemic injuries. These injuries, which can either be asymptomatic or can manifest itself through chest pain brought on by angina pectoris, is partially traced back to insufficient levels of glucose that is needed in order to maintain cellular homeostasis. It is theorized that AICAR’s presence would enable a more efficient carriage of glucose to the areas that may potentially be affected by a cardiac ischemic condition, and it can also potentially stabilize an area in the aftermath of an ischemic condition.
Additionally, it has been theorized that AICAR’s ability to increase the efficiency in which energy is processed and distributed could potentially be help out in prohibiting the restriction of blood flow through an area affected by an ischemic injury. By extension, the presence of AICAR within an animal test subject could at least partially reduce the risk of heart failure in the aftermath of a cardiac ischemic episode.
For Scientific Research Only
While there has been a lot of scientific study that has been conducted on animal test subjects in relation to AICAR and its functionality, it should be noted the peptide is currently still in the research phase. Any information and study relating to AICAR’s functionality and relationship to glucose uptake, insulin resistance, energy regulation, and cardiac ischemic injury should solely be contained to the confines of a strictly controlled environment such as a medical research facility or a laboratory.